Skip to main content

Advertisement

Table 5 Results for cost-effectiveness and cost-utility analyses

From: An economic evaluation alongside a randomized controlled trial evaluating an individually tailored lifestyle intervention compared with usual care in people with Familial Hypercholesterolemia

  Sample size Cost difference in Euros (95% CI) Effect difference (95% CI) ICER Distribution cost-effectivess plane (%NE/SE/SW/NW)
I C  
Main analysis (CEA1) 181 159 LDL-C −237 (−1,386 to 130) −0.14 (−0.34 to 0.07) 1,729 22.5/68.5/7.1/1.9
181 159 QALY −237 (−1,386 to 130) −0.002 (−0.02 to 0.01) 145,899 9.7/30.9/44.2/15.2
Complete case analysis (CEA2) 118 100 LDL-C −364 (−2,030 to 238) −0.14 (−0.37 to 0.08) 2,012 4.6/8.0/55.7/31.7
157 136 QALY −301 (−1,680 to 109) −0.003 (−0.03 to 0.03) 100,347 6.5/25.4/52.5/15.6
Intervention costs as in RCT (CEA3) 181 159 LDL-C −88 (−1,248 to 277) −0.14 (−0.34 to 0.07) 645 39.4/51.6/5.5/3.6
181 159 QALY −88 (−1,248 to 277) −0.002 (−0.02 to 0.01) 54,426 17.1/23.4/33.8/25.7
Hospital admission costs excluded (CEA4) 181 159 LDL-C 94 (−6 to 193) −0.14 (−0.34 to 0.07) −690 88.5/2.4/0.5/8.5
181 159 QALY 94 (−6 to 193) −0.002 (−0.02 to 0.01) −33,676 38.9/1.2/1.7/58.2